Stockreport
BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B [Yahoo! Finance]
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
The deal, approved by the board of directors of both companies, is expected to close in the second quarter of 2026. BioMarin intends to finance this transaction through a combination of its existing cash balance and $3.7 billion in non-convertible debt. Post completion of this acquisition, BioMarin will add Amicus' two marketed therapies, Galafold (for Fabry disease) and Pombiliti-Opfolda (a combination therapy for Pompe disease). Sales of both these drugs have been growing steadily. FOLD has generated combined sales of $449 million from both drugs in the first nine months of 2025, indicating 19% year-over-year growth at CER. Alongside the acquisition news, BioMarin announced that Amicus resolved its patent litigations concerning Galafold with generic drugmakers Aurobindo Pharma and Lupin. FOLD entered separate agreements with each drug manufacturer, wherein it will grant licenses to market generic versions of Galafold in the United States starting on Jan. 30, 2037. As part of
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | BMRN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
BMRN alerts
BMRN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
NEWS
NEWS
- BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target raised by analysts at Truist Financial Corporation from $80.00 to $100.00. They now have a "buy" rating on the stock.[MarketBeat]
- A $4.8 Billion Reason to Buy BioMarin Stock Today [Yahoo! Finance][Yahoo! Finance]
- BioMarin: Amicus Buyout Sparks My Enthusiasm [Seeking Alpha][Seeking Alpha]
- BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push [Yahoo! Finance][Yahoo! Finance]
- BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target raised by analysts at HC Wainwright from $55.00 to $60.00. They now have a "neutral" rating on the stock.[MarketBeat]
- More
BMRN
SEC Filings
SEC Filings
- 12/22/25 - Form 8-K
- 12/19/25 - Form 8-K
- 12/17/25 - Form 8-K
- BMRN's page on the SEC website
- More